Meiji Seika Pharma Presents Positive Findings from Phase II Study of ME3183, Novel Highly-Potent Selective PDE4 Inhibitor, in Patients With Plaque Psoriasis at EADV Congress 2023

Source :: Business Wire. October 13, 2023
Publication Year :: 2023
Abstract: TOKYO -- Meiji Seika Pharma Co., Ltd. (Headquarters: Tokyo, President and Representative Director: Daikichiro Kobayashi) today announced that positive findings from the phase II clinical trial of ME3183, a novel [...]

Subjects :: Meiji Seika Pharma Company Ltd. -- Product development -- Political activity
Psoriasis -- Political aspects
Medical research -- Political aspects
Medicine, Experimental -- Political aspects
Clinical trials -- Political aspects
Pharmaceutical industry -- Product development -- Political activity
Business
Business, international

Tools